Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 9, December, p. 1343–1349

doi: 10.17219/acem/65072

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Higher concentrations of osteoprotegerin in type 1 diabetic patients are related to retinopathy: Results from the Poznań Prospective Study

Agata Grzelka1,A,B,C,D,E,F, Dariusz Naskręt1,A,B,C,D,E,F, Aleksandra Araszkiewicz1,A,C,E,F, Aleksandra Uruska1,B,C,E,F, Małgorzata Wegner2,B,C,E,F, Dorota Zozulińska-Ziółkiewicz1,A,C,E,F

1 Department of Internal Medicine and Diabetology, Poznan University of Medical Sciences, Poland

2 Lipid Metabolism Laboratory, Department of General Chemistry, Chemistry and Clinical Biochemistry, Poznan University of Medical Sciences, Poland

Abstract

Background. Osteoprotegerin (OPG) is an arterial calcification marker which has been associated with vascular damage. Elevated OPG concentrations associated with low-grade inflammatory processes are found in diabetic subjects.
Objectives. The aim of the study was to assess concentrations of OPG in relation to the presence of diabetic complications in patients with diabetes type 1 (DM 1) participating in the Poznań Prospective Study (PoProStu).
Material and Methods. The study included 74 patients with DM1 (48 men) with a median age of 39 years (interquartile range [IQR]: 34–43) and a median 15-year history (IQR: 14–16) of diabetes, who were participants in the PoProStu. Serum OPG concentration was measured using the ELISA method, and serum concentration of C-reactive protein was measured with a high sensitivity test (hsCRP). The visceral adipose index (VAI) was used to determine indirect markers of insulin resistance (IR). The prevalence of microangiopathic diabetes complications was assessed.
Results. Retinopathy was diagnosed in 28 patients (38%), diabetic kidney disease (DKD) in 28 (38%) patients, and neuropathy in 17 (23%) patients. The median OPG level was 43.8 (28.0–74.0) pg/mL. Patients with retinopathy had higher levels of OPG than those without retinopathy: 47.5 (35.0–88.0) vs 35.4 (24.7–69.4) pg/mL (p = 0.04). Positive correlations were observed between OPG concentration and hsCRP (Rs = 0.53; p < 0.001), HbA1c level (Rs = 0.36; p = 0.002), VAI (Rs = 0.23; p = 0.04) and waist circumference (Rs = 0.24; p = 0.04).
Conclusion. Higher concentrations of osteoprotegerin in DM1 patients are related to the presence of retinopathy. The study results indicate that OPG might play a role in the pathogenesis of vascular complications in association with hyperglycemia and low-grade inflammatory processes.

Key words

inflammation, hyperglycemia, osteoprotegerin, diabetic angiopathies, diabetes mellitus type 1

References (30)

  1. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309–319.
  2. Schoppet M. RANK ligand and osteoprotegerin: Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc. Biol 2002;22:549–553.
  3. Doherty TM, Fitzpatrick LA, Inoue D, et al. Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev. 2004;25:629–672.
  4. Bjerre M, Hilden J, Kastrup J, et al. Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial. Scand J Clin Lab Invest. 2014;74:657–664.
  5. Suliburska J, Bogdanski P, Gajewska E, Kalmus G, Sobieska M, Samborski W. The association of insulin resistance with serum osteoprotegerin in obese adolescents. J Physiol Biochem. 2013;69:847–853.
  6. Bjerre M. Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications. SpringerPlus. 2013;2:658.
  7. Lopes-Virella MF, Carter RE, Gilbert GE, et al. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care. 2008;31:2006–2012.
  8. Astrup AS, Tarnow L, Pietraszek L, et al. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: Association with mortality and decline of glomerular filtration rate. Diabetes Care. 2008;31:1170–1176.
  9. Gordin D, Soro-Paavonen A, Thomas MC, et al. Osteoprotegerin is an independent predictor of vascular events in Finnish adults with type 1 diabetes. Diabetes care. 2013;36:1827–1833.
  10. Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol. 2003;149:39–42.
  11. Nybo M, Poulsen MK, Grauslund J, Henriksen JE, Rasmussen LM. Plasma osteoprotegerin concentrations in peripheral sensory neuropathy in type 1 and type 2 diabetic patients. Diabet Med. 2010;27:289–294.
  12. Grzelka A, Araszkiewicz A, Uruska A, Zozulińska-Ziółkiewicz D. Prevalence of anti-thyroid peroxidase in adults with type 1 diabetes participating in Poznań Prospective Study. Adv Clin Exp Med. 2015;24:79–84.
  13. Wilkinson C, Ferris FL, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677–1682.
  14. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49:12–154.
  15. Hofbauer LC. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292:490.
  16. Xiang GD, Xu L, Zhao LS, Yue L, Hou J. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes. 2006;55:2126–2131.
  17. Xiang G, Sun H, Zhao L. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients. Diabetes Res Clin Pract. 2007;76:199–206.
  18. Yu G, Ji X, Jin J, Bu S. Association of serum and vitreous concentrations of osteoprotegerin with diabetic retinopathy. Ann Clin Biochem Int J Biochem Lab Med. 2015;52:232–236.
  19. Wang S, Xu J, Wang M, Chen F, Ding G. Increased plasma osteoprotegerin concentrations in type 1 diabetes with albuminuria. Clin Nephrol. 2013;79:192–198.
  20. Mankoč Ramuš S, Kumše T, Globočnik Petrovič M, Petrovič D, Cilenšek I. SNP rs2073618 of the osteoprotegerin gene is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes. BioMed Res Int. 2013;2013:1–6.
  21. Diabetes Control and Complications Trial Research Group. Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
  22. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CDA; EURODIAB Prospective Complications Study Group. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes – The EURODIAB Prospective Complications Study. Diabetologia. 2005;48:370–378.
  23. Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH. Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia. 2003;46:1402–1407.
  24. Festa A, D’agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int. 2000;58:1703–1710.
  25. Navarro JF, Mora C, Macıéa M, Garcıéa J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis. 2003;42:53–61.
  26. Yaturu S, Rains J, Jain SK. Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-α levels in men with type 2 diabetes. Cytokine. 2008;44:168–171.
  27. de Ciriza CP, Lawrie A, Varo N. OPG expression on endothelial cells and modulation by IL-1B, PDGF, insulin, and glucose. Biochem Physiol Open Access. 2015;4(4):179.
  28. Llaurado G, Ceperuelo-Mallafre V, Vilardell C, et al. Arterial stiffness is increased in patients with type 1 diabetes without cardiovascular disease: A potential role of low-grade inflammation. Diabetes Care. 2012;35:1083–1089.
  29. Ndumele CE, Pradhan AD, Ridker PM. Interrelationships between inflammation, C-reactive protein, and insulin resistance. J Cardiometab Syndr. 2006;1:107–196.
  30. Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: A population-based study. J Am Coll Cardiol. 2007;49:2112–2119.
© Wroclaw Medical University